The London-based drug maker says the agency asked it to carry out clinical trials of its best-selling ADHD drug Vyvanse in children ages four and five. The drug is currently only indicated for use in children with the disorder over the age of six.
from Meta Search Alerts http://ift.tt/1lrxCno
via IFTTThttp://ift.tt/eA8V8J
from Meta Search Alerts http://ift.tt/1lrxCno
via IFTTThttp://ift.tt/eA8V8J
No comments:
Post a Comment
Thanks for your time.